Notice

Final Selection of Development Project (market expansion type) (BIG3 policy designation type)

Final Selection of Development Project (market expansion type) (BIG3 policy designation type) by the Ministry of SMEs and Startups

The Development project of ACPI linked HIS was finally selected for the small and medium-sized business technology innovation development project (market expansion type) (BIG3 policy designation type) by the Ministry of SMEs and Startups.

Regardless of the selection of this project, we have already begun and completed development of manual ACPi, and are proceeding with approval from the Ministry of Food and Drug Safety. Manual ACPi is a drug injection pump, Anyfusion V-100 model, and only the UI for anticancer drug preparation has been changed, and the kit can be prepared with Anyfusion cartridge, so rapid approval is expected.

We have provided concept information and video information to many hospitals, Our device is different from the existing anticancer drug preparation robot, and the anticancer drug preparation robot is forcused in a specific field, and the amount of preparation is limited compared to the price.

ACPi is composed of Manual ACPi, semi-automatic ACPi and full automatic AACPi, which are linked HIS, and hospitals recognized that our device is capable of not only dispensing powders and bottles, but also filling drugs into PCA balloons in clean rooms. Even hospitals that have already decided to purchase robots have given their intentions to purchase them. ACPi, Anyfusion H-100 linked HIS, can be injected to patients without disconnection of kit from bottle or bag, which dramatically reduces human error and Hospitals, MD, Nurse as well as hospital management understand the Anyfusion platform business and are actively giving demands to us.

ACPi has solved the difficulty and inconvenience of extracting anticancer drugs, and the inability to expose oil vapors and reducing the risk of medical accidents in syringes, and also solved the impossible difficulties in the field of pharmaceutical preparation, and is being talked about as an innovative product that cannot be replaced. It is more meaningful that it is a domestic technology, and it is judged that it has the conditions for active purchase at a low price compared to the amount of preparation and cover and functions of all areas.

We will do our best to faithfully reflect the opinions of consumers, develop products that satisfy consumers, and solve the challenges of anticancer drug manufacturers.

Thank you.

Next Selected as a participating company by PHI Digital Healthcare and Yonsei Univ. Severance Hospital
Prev Anyfusion Platform Business consultation with USA, Japan, Germany